content: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date of Report (Date of earliest event reported)       JANUARY 11, 1996 
  
                              ENZON, INC.
  
        (Exact  name  of  registrant  as  specified in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  
  
  
  
  
  <PAGE>
  ITEM 5.  OTHER EVENTS
  
            Enzon, Inc. ("Enzon" or the "Company") announced  it has received
  two  additional  United  States  patents  for  its hemoglobin-based  oxygen
  carrier, PEG-hemoglobin, which has potential application in cancer therapy,
  trauma situations and elective surgery.
  
            PEG-hemoglobin is bovine hemoglobin chemically  modified  by  the
  Company's  exclusive  PEG-technology.   The attachment of PEG (polyethylene
  glycol) extends the blood circulating life  of  a protein, while decreasing
  the patient's natural immune reaction to the protein.
  
            U.S.  Patent No. 5,478,806, "Enhancement  of  Anti-Tumor  Therapy
  with Hemoglobin-Based  Conjugates",  covers  tumor  radiosensitization with
  PEG-hemoglobin,  regardless  of  source  of  hemoglobin  or   type  of  PEG
  conjugate.  Radiosensitization is the process of delivering oxygen to solid
  tumors  to  enhance  response to radiation therapy.  Approximately  800,000
  cases of cancer diagnosed  in  the  U.S.  each  year  involve  solid tumors
  treated  with  radiation.   In  September  1995, Enzon completed a clinical
  trial  with 28 healthy volunteers who received  up  to  45  grams  of  PEG-
  hemoglobin  --  which  is  equivalent to 1.5 units of blood and exceeds the
  dosage required for radiosensitization.   Enzon has begun recruitment for a
  multi-dose,  multi-center  clinical  trial  of   PEG-hemoglobin  in  cancer
  patients receiving radiation therapy.
  
            In the new trial, patients will receive  a  once-a-week  dose  of
  PEG-hemoglobin  for  each  five days of radiation treatment during a three-
  week therapy program.  The Company  believes  that  a  sufficient amount of
  PEG-hemoglobin  will remain in the blood to properly oxygenate  tumors  and
  optimize radiation during the five day course of treatment.
  
            U.S. Patent  No. 5,478,805, "Fractionation of Polyalkylene Oxide-
  Conjugated  Hemoglobin  Solutions",   covers  a  method  of  simultaneously
  fractionating and purifying PEG-hemoglobin  conjugates.  Enzon has received
  other patents on PEG-hemoglobin covering compositions,  methods  of use and
  purification and manufacturing processes.
  
  
  
                              SIGNATURES
  
  
       Pursuant  to the requirements of the Securities Exchange Act of  1934,
  
  the Registrant has  duly  caused  this report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  April 30, 1996
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3775}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96553490"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date of Report (Date of earliest event reported)       JANUARY 11, 1996 
  
                              ENZON, INC.
  
        (Exact  name  of  registrant  as  specified in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
            Enzon, Inc. ("Enzon" or the "Company") announced  it has received
  two  additional  United  States  patents  for  its hemoglobin-based  oxygen
  carrier, PEG-hemoglobin, which has potential application in cancer therapy,
  trauma situations and elective surgery.
  
            PEG-hemoglobin is bovine hemoglobin chemically  modified  by  the
  Company's  exclusive  PEG-technology.   The attachment of PEG (polyethylene
  glycol) extends the blood circulating life  of  a protein, while decreasing
  the patient's natural immune reaction to the protein.
  
            U.S.  Patent No. 5,478,806, "Enhancement  of  Anti-Tumor  Therapy
  with Hemoglobin-Based  Conjugates",  covers  tumor  radiosensitization with
  PEG-hemoglobin,  regardless  of  source  of  hemoglobin  or   type  of  PEG
  conjugate.  Radiosensitization is the process of delivering oxygen to solid
  tumors  to  enhance  response to radiation therapy.  Approximately  800,000
  cases of cancer diagnosed  in  the  U.S.  each  year  involve  solid tumors
  treated  with  radiation.   In  September  1995, Enzon completed a clinical
  trial  with 28 healthy volunteers who received  up  to  45  grams  of  PEG-
  hemoglobin  --  which  is  equivalent to 1.5 units of blood and exceeds the
  dosage required for radiosensitization.   Enzon has begun recruitment for a
  multi-dose,  multi-center  clinical  trial  of   PEG-hemoglobin  in  cancer
  patients receiving radiation therapy.
  
            In the new trial, patients will receive  a  once-a-week  dose  of
  PEG-hemoglobin  for  each  five days of radiation treatment during a three-
  week therapy program.  The Company  believes  that  a  sufficient amount of
  PEG-hemoglobin  will remain in the blood to properly oxygenate  tumors  and
  optimize radiation during the five day course of treatment.
  
            U.S. Patent  No. 5,478,805, "Fractionation of Polyalkylene Oxide-
  Conjugated  Hemoglobin  Solutions",   covers  a  method  of  simultaneously
  fractionating and purifying PEG-hemoglobin  conjugates.  Enzon has received
  other patents on PEG-hemoglobin covering compositions,  methods  of use and
  purification and manufacturing processes.
  
                              SIGNATURES
  
       Pursuant  to the requirements of the Securities Exchange Act of  1934,
  
  the Registrant has  duly  caused  this report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  April 30, 1996
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer